<DOC>
	<DOCNO>NCT01527643</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate bioequivalence two formulation biphasic insulin aspart 50 healthy male subject .</brief_summary>
	<brief_title>Bioequivalence Two Formulations Biphasic Insulin Aspart 50 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Considered generally healthy upon completion medical history physical examination , judge investigator Body Mass Index ( BMI ) 19.030.0 kg/m^2 Glycohemoglobin ( HbA1c ) within laboratory normal range Nonsmokers The receipt investigational drug within last 3 month prior trial . Clinically significant abnormal haematology , biochemistry , urinalysis ECG ( electrocardiogram ) screening test , judge investigator Liver enzyme value ( ALAT ASAT ) exceed 2 time upper reference limit accord local laboratory History current addiction alcohol drug abuse determine investigator ( positive urine drug screen breath alcohol screen ) HIV ( human immunodeficiency virus ) , Hepatitis B C positive Subjects firstdegree relative diabetes mellitus A history multiple and/or severe allergy drug food history anaphylactic reaction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>